FORWARD-LOOKING STATEMENTS
This Proxy Statement contains “forward-looking statements” that involve
risks, uncertainties, and assumptions. Forward-looking statements are all statements, other than statements of historical facts, that discuss our current expectation and projections relating to our strategy, future operations, future financial
position, future revenues, projected costs, prospects, plans, and objectives of management. These statements may be preceded by, followed by or include the words “aim,” “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “forecast,”
“intend,” “likely,” “may,” “outlook,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would,” the negatives or plurals thereof, and other words and terms of similar meaning, although not all forward-looking statements
contain these identifying words.
We have based these forward-looking statements on our current
expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be
correct. You should understand that all forward-looking statements are subject to other important factors and risks detailed in our Form 10-K. In light of these risks and uncertainties, we may not actually achieve the plans, intentions or
expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the
forward-looking statements we make. These forward-looking statements speak only as of the date of this proxy statement. We undertake no obligation, and specifically decline any obligation, to publicly update or revise any forward-looking
statements, even if experience or future developments make it clear that projected results expressed or implied in such statements will not be realized, except as may be required by law.
OTHER MATTERS
The Board knows of no other business which will be presented to the 2023
Annual Meeting. If any other business is properly brought before the 2023 Annual Meeting, proxies in the enclosed form will be voted in accordance with the judgment of the individuals named as proxies on the proxy card.
STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR
If you wish to submit a proposal to be considered for inclusion in next
year’s proxy materials or nominate a director, your proposal must be in proper form according to SEC Regulation 14A, Rule 14a-8 and received by the Secretary of the Company no later than December 28, 2023. Proposals received after that date
will not be included in the proxy materials we send out in connection with the 2024 Annual Meeting of Stockholders. If a proposal is received before that date, the proxies that management solicits for the meeting may still exercise
discretionary voting authority on the proposal under circumstances consistent with the proxy rules of the SEC. To be timely in accordance with our By-laws, stockholder notice of any proposal, other than a stockholder proposal intended to be
included in our proxy statement and submitted pursuant to Rule 14a-8 promulgated under the Securities Exchange Act of 1934, must be received by us not earlier than November 28, 2023 and not later than December 28, 2023; provided, however, that
in the event that the date of the 2024 Annual Meeting of Stockholders is more than 30 days before or more than 60 days after the anniversary date of the 2023 Annual Meeting of Stockholders, notice by the stockholder to be timely must be
delivered not earlier than the close of business on the 90th day prior to such 2023 Annual Meeting of Stockholders and not later than the close of business on the later of the 60th day prior to such 2024 Annual Meeting of Stockholders or the
10th day following the day on which we make a public announcement of the date of the 2024 Annual Meeting of Stockholders. All stockholder proposals should be marked for the attention of Chief Legal Officer and Corporate Secretary, c/o Amicus
Therapeutics, Inc., 3675 Market Street, Philadelphia, Pennsylvania 19104.
Our Annual Report on Form 10-K for the fiscal year
ended December 31, 2022 (other than the exhibits thereto), filed with the SEC, which provides additional information about us, is available on the Internet at www.amicusrx.com and is available in paper
form to beneficial owners of our Common Stock without charge upon written request to Secretary, c/o Amicus Therapeutics, Inc., 3675 Market Street, Philadelphia, Pennsylvania 19104.
DELIVERY OF PROXY MATERIALS
Some banks, brokers, and other nominee record holders may be
participating in the practice of “householding” proxy statements and annual reports. This means that only one copy of this Proxy Statement, the Notice of 2022 Annual Meeting of Stockholders and our Annual Report to Stockholders may have been
sent to multiple stockholders in your household. Householding is designed to reduce duplicate mailings and save significant printing and postage costs. If you receive a household mailing this year and would like to receive additional copies of
this Proxy Statement, the Notice of 2023 Annual Meeting of Stockholders, and our Annual Report to Stockholders, please call us at (215) 921-7600 or send a written request to Chief Legal Officer and Corporate Secretary, c/o Amicus Therapeutics,
Inc., 3675 Market Street, Philadelphia, Pennsylvania 19104. If you want to receive separate copies of our Proxy Statement, Notice of our Annual Meeting of Stockholders and our Annual Report to Stockholders in the future, or if you are receiving
multiple copies and would like to receive only one copy for your household, you should contact your bank, broker, or other nominee record holder, or you may contact us at the above address and phone number.